ACOR News and Press, Acorda Therapeutics Inc. From 12/23/19

Acorda Therapeutics, Inc. (Nasdaq: ACOR) (the “Company”) today announced that it has entered into agreements with a limited number of institutional investors who are holders of the Company’s 1.75% Convertible Senior Notes due 2021 (the “Existing Convertible Notes&#...

Acorda Therapeutics, Inc. (NASDAQ: ACOR ) today announced that its Board of Directors has elected John Kelley to serve as non-executive board Chair, effective November 25, 2019. Mr. Kelley has been a board member at Acorda since 2008. “I am delighted that John will be chairing Aco...

Acorda Therapeutics, Inc. (Nasdaq: ACOR ) today announced that Jane Wasman, President, International & General Counsel, is resigning from the company effective at the end of this year. Ms. Wasman plans to expand her role as a member of corporate boards, and to provide consulting services...

Acorda Therapeutics ( ACOR +21% ) is up on triple normal volume in response to its Q3 results released after the close yesterday. More news on: Acorda Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...

Gainers : NextCure (NASDAQ: NXTC ) +183% . Fulgent Genetics (NASDAQ: FLGT ) +35% . NIO (NYSE: NIO ) +28% . Acorda Therapeutics (NASDAQ: ACOR ) +26% . EverQuote (NASDAQ: EVER ) +27% . Forterra (NASDAQ: FRTA ) +25% . Gaia (NASDAQ: GAIA ) +23% . Agile Therapeutics (NASDAQ: AGRX ) +23%...

The following slide deck was published by Acorda Therapeutics, Inc. in conjunction with their 2019 Q3 earnings Read more ...

Acorda Therapeutics, Inc. (ACOR) Q3 2019 Earnings Conference Call November 5, 2019 04:30 p.m. ET Company Representatives Ron Cohen - Chief Executive Officer Lauren Sabella - Chief Commercial Officer David Lawrence - CTO, Chief of Business Operations & Principal Accounting Off...

Acorda Therapeutics (NASDAQ: ACOR ): Q3 Non-GAAP EPS of -$0.46 beats by $0.05 ; GAAP EPS of -$5.55 misses by $4.79 . More news on: Acorda Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Corporate restructuring implemented to reduce costs and focus resources on INBRIJA® (levodopa inhalation powder) launch INBRIJA 3Q 2019 net sales of $5 million INBRIJA approved in the European Union AMPYRA ® (dalfampridine) 3Q 2019 net sales of $38 million 2019 y...

Camber Energy (NYSEMKT: CEI ) +53% . More news on: Camber Energy, Inc., Wright Medical Group N.V., Enlivex Therapeutics Ltd., Stocks on the move, Read more ...